Abin Thomas

12PUBLICATIONS
73CO-AUTHORS
Haematological tumoursCancer therapy (excl. chemotherapy and radiation therapy)Medical infection agents (incl. prions)Predictive and prognostic markersRehabilitation
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (12)

|Jun 25, 2026
Combining Quizartinib with intensive chemotherapy in older patients with newly diagnosed AML: results of the UK NCRI AML18 Trial.

|Nov 14, 2025
CPX-351 vs daunorubicin, cytarabine, and gemtuzumab ozogamicin in older adults with non-adverse-risk AML: the NCRI AML18 trial.

Steven Knapper, Laura W Dillon, Malavika Babu

|Sep 30, 2025
Safety and efficacy of combining midostaurin and gemtuzumab ozogamicin with induction chemotherapy in FLT3-mutated AML.

Nigel Russell, Jad Othman, Oliver Cumming

|May 22, 2025
A revised prognostic model for patients with acute myeloid leukemia and first relapse.

Niek G van der Maas, Dimitri Breems, Clara P W Klerk

|Feb 28, 2025
Reply to: Treatment Intensification Based on Residual Disease in Elderly Patients With AML.

Nigel H Russell, Abin Thomas, Sylvie D Freeman

|Nov 18, 2024
Treatment Intensification With Either Fludarabine, AraC, G-CSF and Idarubicin, or Cladribine Plus Daunorubicin and AraC on the Basis of Residual Disease Status in Older Patients With AML: Results From the NCRI AML18 Trial.

Nigel H Russell, Abin Thomas, Robert K Hills

Pageof 2

Frequent Collaborators

8 joint publications

Sylvie D Freeman

7 joint publications

Steven Knapper

4 joint publications

Priyanka Mehta

4 joint publications

Mike Dennis